News | Jiksak Bioengineering

Notice of Patent Granted

ghweb — Tue, 07 Apr 2026 01:22:57 +0000

We are pleased to announce that the following patent application related to our Neuron DDS technology has been granted.

Title of Invention: Targeting Agent
Application Number: Japanese Patent Application No. 2024-517316
Patent Holder: Jiksak Bioengineering, Inc.
Overview: This patent relates to a technology for delivering substances to cells in central nervous system using antibodies that target neuronal synapses located in the periphery. This technology enables selective delivery to neurons, which was previously difficult to achieve, and is expected to find applications in the analysis of neural function and in therapeutic treatments.

We believe this patent grant will further strengthen the intellectual property foundation that supports our research and development activities and business advancement.

The post Notice of Patent Granted first appeared on Jiksak Bioengineering.

Announcing Poster Presentation at the 36th International Symposium on ALS/MND

ghweb — Thu, 27 Nov 2025 15:35:07 +0000

We are pleased to announce that our Co-CEO, Dr. Yumoto, will present a poster on Neuron DDS at the 36th International Symposium on ALS/MND (MNDA Symposium).
We are honored to have been given this opportunity to present our cutting edge Neuron DDS technology at one of the largest and most influential international conferences in the ALS/MND research field. Only a limited number of abstracts are accepted each year after a rigorous review process.

[Symposium Details]
Dates: December 5 (Fri) – 7 (Sun), 2025 ※U.S. (PST)
Location: Loews Coronado Bay Resort, San Diego, California, USA
Poster Theme: Pre-clinical Therapeutic Strategies
TST-01:Neuron-selective delivery of oligonucleotides via synaptic vesicle recycling:A strategy to bypass the CNS barrier and optimize intracellular exposure.

In this study, we demonstrated a neuron-targeted delivery system that can transport both oligonucleotides and small-molecule therapeutics using synaptic vesicle recycling as the uptake route to neurons .
This approach enables direct molecular exposure into motor neurons and may offer a practical path to overcoming the long-standing delivery challenges in ALS drug development.
If you will be attending the symposium, we warmly welcome you to visit our poster.
We look forward to discuss our research and explore potential collaboration opportunities with colleagues in the field.

The post Announcing Poster Presentation at the 36th International Symposium on ALS/MND first appeared on Jiksak Bioengineering.

Our Technology Featured in an Advertorial on Nature.com

ghweb — Fri, 14 Nov 2025 01:54:24 +0000

Our advertisement feature, A new route to the brain and spine via the ‘vesicle express’, was published on 13 November 2025, as part of Technology Feature Neuroscience: Building better sensors in the online version of Nature, a weekly international journal publishing the finest peer-reviewed research in science and technology.

The advertisement feature can be found here: https://www.nature.com/articles/d42473-025-00295-4

Briefly, the article describes systemic administration of Jiksak Neuron DDS technology can deliver therapeutics to specific regions in spinal cord and brain through motor neurons segment loaded with vesicles located outside of the CNS barriers.

The post Our Technology Featured in an Advertorial on Nature.com first appeared on Jiksak Bioengineering.

Jiksak Enters Joint Research Agreement with Keio University for ALS Drug Discovery

ghweb — Fri, 14 Nov 2025 01:52:11 +0000

Jiksak is pleased to announce that it has entered into a joint research agreement with Keio University Regenerative Medicine Research Center “Director; Professor Hideyuki Okano”.
This collaboration aims to advance the development of novel therapies for neurological disorders, with a particular focus on amyotrophic lateral sclerosis (ALS) drug discovery. By combining the cutting-edge expertise and innovative technologies from both parties, the partnership seeks to open new avenues for ALS drug discovery and development. Through continued industry–academia collaboration, Jiksak remains committed to driving progress in neuroscience by promoting research and development toward overcoming intractable neurological diseases.

The post Jiksak Enters Joint Research Agreement with Keio University for ALS Drug Discovery first appeared on Jiksak Bioengineering.

Jiksak Bioengineering was Awarded AbbVie Special Mentoring Program at AbbVie Japan Innovation Award

ghweb — Wed, 01 Oct 2025 07:43:29 +0000

We are pleased to announce that Jiksak Bioengineering has been awarded the AbbVie Special Mentoring Program at the AbbVie Japan Innovation Award, organized by AbbVie GK and U.S.-based BioLabs.

This award supports startups and research institutions engaged in innovative research and development, promoting the advancement of next-generation medicine through open innovation. The potential and developability of our cutting edge Neuron Drug Delivery System has been recognized through this award, providing us with a valuable opportunity to participate in this significant mentoring program.

Taking this award as a new starting point, we will accelerate our innovative research and development, striving to contribute to medical advancement and to bring new therapeutics to patients faster.

Article link：
https://kyodonewsprwire.jp/release/202510016315

The post Jiksak Bioengineering was Awarded AbbVie Special Mentoring Program at AbbVie Japan Innovation Award first appeared on Jiksak Bioengineering.

New Paper Published on Our DLC Technology

ghweb — Thu, 12 Jun 2025 00:35:45 +0000

Our proprietary DLC technology for drug discovery has been published in Molecular Therapy – Methods & Clinical Development, an open access journal of the Cell Press family.

Title: Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(25)00071-3

The post New Paper Published on Our DLC Technology first appeared on Jiksak Bioengineering.

Jiksak Bioengineering Inc. and Teijin Pharma Ltd. signed a joint research agreement to identify novel drug target genes for neurodegenerative diseases.

ghweb — Mon, 02 Sep 2024 00:00:56 +0000

We are pleased to announce that we have entered into a joint research agreement with Teijin Pharma Ltd. (headquartered in Chiyoda-ku, Tokyo; Masaki Taneda, President & CEO; hereinafter referred to as Teijin Pharma). The purpose of this joint research is to identify novel drug target genes for neurological intractable diseases using Jiksak’s pre-synaptogenesis-inducing microbeads. This research is expected to play an important role in the elucidation of pathological conditions and the development of treatments. Jiksak and Teijin Pharma will contribute to the development of new treatments for neurological intractable diseases by utilizing cutting-edge biotechnology.

The post Jiksak Bioengineering Inc. and Teijin Pharma Ltd. signed a joint research agreement to identify novel drug target genes for neurodegenerative diseases. first appeared on Jiksak Bioengineering.

Papers related to our organoid technology have been published.

ghweb — Wed, 22 May 2024 06:42:19 +0000

Two papers on the research conducted by our scientific advisor, Associate Professor Yoshiho Ikeuchi, have been published. You can view the papers at the following links.

Nature Communications

Complex activity and short-term plasticity of human cerebral organoids reciprocally connected with axons

https://www.nature.com/articles/s41467-024-46787-7

Stem Cell Reports

ARID1B controls transcriptional programs of axon projection in an organoid model of the human corpus callosum

https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00141-3

The post Papers related to our organoid technology have been published. first appeared on Jiksak Bioengineering.

We have commenced collaborative research and development with Molmir Corporation.

ghweb — Mon, 04 Sep 2023 07:35:17 +0000

We have recently entered into a collaborative research agreement with Molmir Corporation (hereinafter referred to as “Molmir”), a biotechnology venture dedicated to drug development for Amyotrophic Lateral Sclerosis (ALS). Molmir’s molecular dynamics assessment technology excels in in vitro evaluations, while Jiksak’s neural organoid technology demonstrates strength in assessments within neural tissues. By integrating the distinct technologies of both companies, we will accelerate the development of ALS therapeutic drugs.

Molmir Co., Ltd. announcement link

https://www.molmir.co.jp/

The post We have commenced collaborative research and development with Molmir Corporation. first appeared on Jiksak Bioengineering.

Development of Antibodies for Drug Linked Carrier～Jiksak and MBL announce the jointly developed antibodies for Drug Linked Carrier～

ghweb — Mon, 24 Jul 2023 15:00:42 +0000

Jiksak Bioengineering Inc (hereinafter referred to as Jiksak; co-CEO: Jiro Kawada) under its drug discovery project has been developing a drug delivery technology using pharmaceutical antibodies called Drug Linked Carrier (DLC) for the treatment of motor neuron diseases. The line-up of antibodies against several proteins required for DLC has been jointly developed with the leading antibody development company, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD (MBL).

Jiksak had obtained DLC data that supports the hypothesis of DLC Mode of Action, which shows that the antibodies are effective as a drug delivery system.
Further development of DLC drug delivery system will be undertaken for the benefit of patients with neurological intractable diseases.

MBL press release.

https://www.mbl.co.jp/company/info_list.html

The post Development of Antibodies for Drug Linked Carrier
～Jiksak and MBL announce the jointly developed antibodies for Drug Linked Carrier～ first appeared on Jiksak Bioengineering.